Sign In
Buy OCUL
$8.35
+0.0400 (+0.481%)
At Close: Jun 03, 2026
Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026
05:00pm, Friday, 13'th Feb 2026
Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET Detailed SOL-1 data to be presented at the 49 th Macula Society Annual Meeting BEDFORD, Mass., Feb. 13, 2026 (GLOBE NEWSW
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 06'th Feb 2026
BEDFORD, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today an
Stock Traders Purchase Large Volume of Put Options on Ocular Therapeutix (NASDAQ:OCUL)
01:36am, Friday, 06'th Feb 2026
Ocular Therapeutix, Inc. (NASDAQ: OCUL - Get Free Report) saw some unusual options trading activity on Wednesday. Traders purchased 25,044 put options on the company. This represents an increase of 47
Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates
09:11am, Thursday, 05'th Feb 2026
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.29 per share a year ago.
Ocular Therapeutix: Why SOL-1 Trial Outcome Is Likely Positive
07:30am, Wednesday, 04'th Feb 2026
Ocular Therapeutix (OCUL) is a Strong Buy, driven by the pivotal SOL-1 Phase 3 trial for AXPAXLI™ in wet AMD, with topline results expected Q1 2026. AXPAXLI™ leverages proven science and a de-risk
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 23'rd Jan 2026
BEDFORD, Mass., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today an
Strength Seen in Ocular Therapeutix (OCUL): Can Its 6.1% Jump Turn into More Strength?
10:31am, Thursday, 15'th Jan 2026
Ocular Therapeutix (OCUL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price i
Biotech outperformance expected to continue in 2026, Baird analysts say
11:46am, Friday, 09'th Jan 2026
The biotechnology sector's strong fundamentals and robust innovation could continue to drive outperformance this year, according to Baird analysts. The firm noted that while macroeconomic risks such a
Head to Head Comparison: Ocular Therapeutix (NASDAQ:OCUL) & Sonoma Pharmaceuticals (NASDAQ:SNOA)
01:12am, Monday, 05'th Jan 2026
Sonoma Pharmaceuticals (NASDAQ: SNOA - Get Free Report) and Ocular Therapeutix (NASDAQ: OCUL - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two comp
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of “Moderate Buy” from Analysts
02:06am, Monday, 15'th Dec 2025
Ocular Therapeutix, Inc. (NASDAQ: OCUL - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the fourteen brokerages that are presently covering the stock, Marketbeat.com rep
Ocular Therapeutix Stock Skyrockets On Faster FDA Path For Vision Drug
12:59pm, Monday, 08'th Dec 2025
Ocular Therapeutix Inc. (NASDAQ: OCUL) stock surged on Monday after the company announced plans to accelerate the timeline for submitting a New Drug Application (NDA) for Axpaxli (OTX-TKI) in the trea
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Friday, 05'th Dec 2025
BEDFORD, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today an
Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 82.48%: Read This Before Placing a Bet
10:56am, Thursday, 20'th Nov 2025
The consensus price target hints at an 82.5% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin
Ocular Therapeutix, Inc. (OCUL) Q3 2025 Earnings Call Transcript
03:16pm, Tuesday, 04'th Nov 2025
Ocular Therapeutix, Inc. (OCUL) Q3 2025 Earnings Call Transcript
Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates
09:45am, Tuesday, 04'th Nov 2025
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.26 per share a year ago.
